Novartis Ag Adr (NVS)

11:00 AM

Dermatology Market to Worth USD 2.75 Billion Size by 2034 - GlobeNewswire Inc.

11:00 AM

Aug 19, 2025

Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn

Aug 19, 2025

Aug 18, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Aug 18, 2025

Aug 17, 2025

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com

Aug 17, 2025

Aug 10, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva

Aug 10, 2025

Aug 07, 2025

What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar

Aug 07, 2025

Jul 31, 2025

Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail

Jul 31, 2025

Jul 29, 2025

INCY's Q2 Earnings & Revenues Beat Estimates On Higher Product Sales - Barchart.com

Jul 29, 2025

Jul 25, 2025

NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jul 25, 2025

Jul 18, 2025

Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar

Jul 18, 2025

Jul 17, 2025

Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com

Jul 17, 2025

Jul 17, 2025

Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria

Jul 17, 2025

Jul 17, 2025

Novartis Earnings: Double-Digit Sales Growth Supports Another Upgrade to Full-Year Guidance - Morningstar

Jul 17, 2025

Jul 15, 2025

Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com

Jul 15, 2025

Jul 15, 2025

Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - Yahoo Finance

Jul 15, 2025

Jul 10, 2025

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com

Jul 10, 2025

Jul 03, 2025

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView

Jul 03, 2025

Jul 01, 2025

Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com

Jul 01, 2025

Jun 25, 2025

Novartis completes acquisition of Regulus Therapeutics - Novartis

Jun 25, 2025

Jun 16, 2025

5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com

Jun 16, 2025

Jun 11, 2025

NVO Stock Gains After Parvus Asset Management Builds Stake - Barchart.com

Jun 11, 2025

Jun 10, 2025

The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 - Barchart.com

Jun 10, 2025

Jun 03, 2025

Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com

Jun 03, 2025

May 29, 2025

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

May 29, 2025

May 28, 2025

Why Value Investing Has Worked Better Outside the US - Morningstar

May 28, 2025

May 27, 2025

Novartis announces commencement of tender offer to acquire Regulus Therapeutics - Novartis

May 27, 2025